Skip to content

Melanotan II Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

Common Side Effects:

  • Nausea (most frequent, especially with initial doses)
  • Facial flushing and warmth
  • Fatigue or drowsiness
  • Appetite suppression
  • Spontaneous or prolonged erections in men

Less Common Side Effects:

  • Darkening of existing moles and freckles
  • Development of new nevi (moles)
  • Injection site reactions (redness, pain, swelling)
  • Headache
  • Dizziness

Concerns Requiring Attention:

Mole darkening raises melanoma concerns due to MT-II's direct stimulation of melanocytes. Multiple published case reports in peer-reviewed journals, including the British Journal of Dermatology, have documented melanomas arising during MT-II use. Both the UK's MHRA and Australia's TGA have issued formal safety warnings specifically citing melanoma risk. While definitive population-level causality has not been established through large-scale epidemiological studies, the evidence goes well beyond theoretical concern. Those with numerous atypical moles, a personal or family history of melanoma, or very fair skin (Fitzpatrick type I) are at particular risk. Regular dermatological monitoring is advisable for anyone using MT-II.

The Wessells 1998 study showed dose-dependent erections lasting 1–5 hours in subjects receiving MT-II, and priapism (erection lasting more than 4 hours) is a recognized risk. Priapism constitutes a urological emergency requiring immediate attention, as delayed treatment can result in permanent erectile dysfunction.

Products sourced from unregulated channels may vary significantly in purity, potency, and sterility, introducing additional safety risks independent of the compound itself.

Frequently Asked Questions

Yes, MT-II is used by both men and women for tanning purposes. Women may experience increased libido as a side effect. Pregnant or breastfeeding women should avoid MT-II due to lack of safety data.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777-84.
  2. Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology. 1998;160(2):389-93.
  3. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-30.
  4. Fan W, et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-8.
  5. Brennan R, et al. Melanotan II: a review of the evidence for efficacy and safety. Dermatology Online Journal. 2019.
  6. U.S. Food and Drug Administration. Tainted Sexual Enhancement Products. FDA Consumer Updates.
  7. World Anti-Doping Agency. The 2024 Prohibited List. WADA.
  8. Hruby VJ, et al. Cyclic lactam alpha-melanotropin analogues with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. Journal of Medicinal Chemistry. 1995;38(18):3454-61.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”